Correlation Engine 2.0
Clear Search sequence regions
Bookmark Forward

QuickView for Tenecteplase (compound)


DrugBank
Identification
Name: tenecteplase
Name (isomeric): DB00031
Drug Type: biotech
Synonyms:
tPA; t-plasminogen activator; Tissue-type plasminogen activator precursor; t- PA
Brand: TNKase (Genentech Inc)
Category: Thrombolytic Agents
CAS number: 191588-94-0
Pharmacology
Indication: For treatment of myocardial infarction and lysis of intracoronary emboli
Pharmacology: Tenecteplase is a fibrin-specific tissue-plasminogen activator. It binds to fibrin rich clots and cleaves the Arg/Val bond in plasminogen to form plasmin. Plasmin in turn degrades the fibrin matrix of the thrombus, thereby exerting its thrombolytic action. This helps eliminate blood clots or arterial blockages that cause myocardial infarction.
Mechanism of Action: Tenecteplase binds to fibrin rich clots via the fibronectin finger-like domain and the Kringle 2 domain. The protease domain then cleaves the Arg/Val bond in plasminogen to form plasmin. Plasmin in turn degrades the fibrin matrix of the thrombus, thereby exerting its thrombolytic action.
Half Life: 1.9 hours (mammalian reticulocytes, in vitro) >20 hours (yeast, in vivo) >10 hours (Escherichia coli, in vivo)
Clearance: 99 - 119 mL/min [acute myocardial infarction patients]
Affected organisms: Humans and other mammals
Interactions
Drug interaction:
AprotininAprotonin may antagonize the effect of Tenecteplase. Monitor for decreased effects of Tenecteplase.
GinsengIncreased risk of bleeding.
Drotrecogin alfaIncreased risk of bleeding.
Ginkgo bilobaAdditive anticoagulant/antiplatelet effects may increase bleed risk. Concomitant therapy should be avoided.
TiclopidineIncreased bleeding risk. Monitor for signs of bleeding.

Targets